Considering any disease, it is known that there are differences in response to the standart dose of medical treatment among individuals. This causes problems such as treatment nonresponsiveness or observation of side effects in clinic applications. It is known that many factors such as age, weight, gender, disease itself or drug interactions may effect the response to the drug used. As pharmacogenetic provides patient-specific treatment, it brings innovations in the treatment of all diseases, mainly cancer and psychiatric diseases. In our compilation, we will cover the developments and innovations in this field of science.
Published in | Journal of Family Medicine and Health Care (Volume 1, Issue 3) |
DOI | 10.11648/j.jfmhc.20150103.11 |
Page(s) | 33-35 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2015. Published by Science Publishing Group |
Pharmacogenetic, Individual Treatment, Gene
[1] | Karabulut HG. Farmakogenetik: Laboratuvardan Klinik Uygulamaya. Turkiye Klinikleri J Med Sci 2010; 30(Suppl 1): S5-S15. |
[2] | Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119-37. |
[3] | Percin EF. Hastalık ve Gen tedavisi- Farmakogenetik. Meslek ici surekli egitim dergisi. 2007; 19-20: 16-25. |
[4] | Lanfear DE, McLeod HL. Pharmacogenetics: using DNA to optimize drug therapy. Am Fam Physician 2007; 76(8): 1179-82. |
[5] | Benlier N. Bireye Ozgu Tedavi, Farmakogenetik. Bilim ve Bilim Adami 2014. http://bilimvebilimadami.com/bireye-ozgu-tedavi-farmakogenetik. (Accessed Nov 06, 2015). |
[6] | Weinshilboum RM, Wang L. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu Rev Genomics Hum Genet 2006; 7: 223-45. |
[7] | Ilgin Ruhi H. Meme Kanserinde Farmakogenetik. Turkiye Klinikleri J Med Sci 2010; 30 (Suppl 1): S16-S21. |
[8] | http://www.slideshare.net/TasneemHamadaHefney/pharmacogenetics-27975067?related=1 (Accessed Nov 13, 2015). |
[9] | Brennan FX, Gardner KR, Lombard J et al. A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients with Mood and Anxiety Disorders. Prim Care Companion CNS Disord. 2015 Apr 16; 17(2). |
[10] | Saglam E. Farmakogenetik Testlerde Farmakologlar Nerede Durmalidir? TFD-KFÇG Elektronik Bulteni 2008; 08: 1-3. |
[11] | Laleli Y, Laleli Sahin E. Farmakogenetik ve Farmakoekonomi. Turkiye Klinikleri J Med Sci 2010; 30 (Suppl 1): S37-S46. |
[12] | D. Brixner, E. Biltaji, A. Bress et al. The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ. 2015 Oct 19: 1-40. |
[13] | Faulkner E, Annemans L, Garrison L, et al. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health. 2012; 15(8): 1162-1171. |
[14] | Meckley LM, Neumann PJ. Personalized medicine: factors influencing reimbursement. Health Policy. 2010; 94(2): 91-100. |
[15] | US Food and Drug Administration. Table of Pharmacogenomic Biomarkers in Drug Labels. Available from: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm. (Accessed Nov 10, 2015). |
[16] | Frueh FW, Amur S, Mummaneni P, et al. Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy. 2008; 28(8): 992–998. |
[17] | Haga SB, Mills R, Moaddeb J. Pharmacogenetic information for patients on drug labels. Pharmgenomics Pers Med. 2014 Oct 3; 7: 297-305. |
[18] | Demirkazik A, Tukun FA. Kanserde Bireysellestirilmis Tedavi: Neden Farmakogenetik? Turkiye Klinikleri J Med Sci 2010; 30 (Suppl 1): S1-S4. |
APA Style
Onur Ozturk, Izzet Fidanci. (2015). A General Look at Pharmacogenetic and Its Future. Journal of Family Medicine and Health Care, 1(3), 33-35. https://doi.org/10.11648/j.jfmhc.20150103.11
ACS Style
Onur Ozturk; Izzet Fidanci. A General Look at Pharmacogenetic and Its Future. J. Fam. Med. Health Care 2015, 1(3), 33-35. doi: 10.11648/j.jfmhc.20150103.11
AMA Style
Onur Ozturk, Izzet Fidanci. A General Look at Pharmacogenetic and Its Future. J Fam Med Health Care. 2015;1(3):33-35. doi: 10.11648/j.jfmhc.20150103.11
@article{10.11648/j.jfmhc.20150103.11, author = {Onur Ozturk and Izzet Fidanci}, title = {A General Look at Pharmacogenetic and Its Future}, journal = {Journal of Family Medicine and Health Care}, volume = {1}, number = {3}, pages = {33-35}, doi = {10.11648/j.jfmhc.20150103.11}, url = {https://doi.org/10.11648/j.jfmhc.20150103.11}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jfmhc.20150103.11}, abstract = {Considering any disease, it is known that there are differences in response to the standart dose of medical treatment among individuals. This causes problems such as treatment nonresponsiveness or observation of side effects in clinic applications. It is known that many factors such as age, weight, gender, disease itself or drug interactions may effect the response to the drug used. As pharmacogenetic provides patient-specific treatment, it brings innovations in the treatment of all diseases, mainly cancer and psychiatric diseases. In our compilation, we will cover the developments and innovations in this field of science.}, year = {2015} }
TY - JOUR T1 - A General Look at Pharmacogenetic and Its Future AU - Onur Ozturk AU - Izzet Fidanci Y1 - 2015/12/21 PY - 2015 N1 - https://doi.org/10.11648/j.jfmhc.20150103.11 DO - 10.11648/j.jfmhc.20150103.11 T2 - Journal of Family Medicine and Health Care JF - Journal of Family Medicine and Health Care JO - Journal of Family Medicine and Health Care SP - 33 EP - 35 PB - Science Publishing Group SN - 2469-8342 UR - https://doi.org/10.11648/j.jfmhc.20150103.11 AB - Considering any disease, it is known that there are differences in response to the standart dose of medical treatment among individuals. This causes problems such as treatment nonresponsiveness or observation of side effects in clinic applications. It is known that many factors such as age, weight, gender, disease itself or drug interactions may effect the response to the drug used. As pharmacogenetic provides patient-specific treatment, it brings innovations in the treatment of all diseases, mainly cancer and psychiatric diseases. In our compilation, we will cover the developments and innovations in this field of science. VL - 1 IS - 3 ER -